SCHEMBL5102172

SCHEMBL5102172

CSc1nccc(-n2ncc3ccc(NC(C)=O)cc32)n1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IRAK4 Q9NWZ3 4/20 0.49
CSNK2A1 P68400 9/20 0.46
GSK3B P49841 2/20 0.46
HIPK2 Q9H2X6 1/20 0.46
ALDH1A1 P00352 1/20 0.43
PIM1 P11309 6/20 0.42
PIM2 Q9P1W9 2/20 0.41
PIM3 Q86V86 2/20 0.40
PIK3CA P42336 2/20 0.40
PIK3CD O00329 1/20 0.40
DYRK3 O43781 1/20 0.40
CDK2 P24941 1/20 0.40
PIK3CB P42338 1/20 0.40
PIK3CG P48736 1/20 0.40
KDM4E B2RXH2 1/20 0.39
MEN1 O00255 1/20 0.39
NPC1 O15118 1/20 0.39
GLA P06280 1/20 0.39
MAPT P10636 1/20 0.39
TNNI3 P19429 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5096302 0.81 IRAK4 (0.46) IRAK4CSNK2A1GSK3BHIPK2ALDH1A1
SCHEMBL5090482 0.77 IRAK4 (0.52) IRAK4PIM3PAK4PIKFYVE
SCHEMBL3817344 0.76 MAPK8 (0.66) IRAK4CSNK2A1GSK3BHIPK2CDK2
SCHEMBL3819868 0.76 MAPK8 (0.66) IRAK4CSNK2A1GSK3BHIPK2CDK2
SCHEMBL5090382 0.75 KDR (0.47) IRAK4ALDH1A1MEN1NPC1MAPT
SCHEMBL3824181 0.74 MKNK1 (0.48) IRAK4ALDH1A1CDK2MAPTPAK4
SCHEMBL30006626 0.71 MAPT (0.53) ALDH1A1KDM4EMEN1NPC1GLA
SCHEMBL5096332 0.71 ROCK1 (0.42) IRAK4ALDH1A1KDM4EMAPTRAB9A
SCHEMBL30459759 0.68 ROCK1 (0.45) ALDH1A1PIM3DYRK3MEN1MAPT
SCHEMBL17683138 0.68 ROCK1 (0.45) ALDH1A1PIM3DYRK3MEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8399462-B2 4-[4-(4-benzyloxy-indol-1-yl)-pyrimidin-2-ylamino]-cyclohexanol; autoimmune, inflammatory, metabolic, neurological diseases as well as cancer and pain ROCHE PALO ALTO LLC (US) 2013-03-19 US disclosed
US-8399462-B2 4-[4-(4-benzyloxy-indol-1-yl)-pyrimidin-2-ylamino]-cyclohexanol; autoimmune, inflammatory, metabolic, neurological diseases as well as cancer and pain ROCHE PALO ALTO LLC (US) 2013-03-19 US disclosed
US-8399462-B2 4-[4-(4-benzyloxy-indol-1-yl)-pyrimidin-2-ylamino]-cyclohexanol; autoimmune, inflammatory, metabolic, neurological diseases as well as cancer and pain ROCHE PALO ALTO LLC (US) 2013-03-19 US disclosed
CN-101547917-A Substituted pyrimidines and their use as JNK modulators HOFFMANN LAROCHE (CH) 2009-09-30 CN disclosed
US-20080146565-A1 JNK modulators ROCHE PALO ALTO LLC 2008-06-19 US disclosed
US-20080146565-A1 JNK modulators ROCHE PALO ALTO LLC 2008-06-19 US disclosed
US-20080146565-A1 JNK modulators ROCHE PALO ALTO LLC 2008-06-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080146565-A1 JNK modulators MAPKAPK2, MAPKAPK3, MAP3K10 IRAK4 447/4885CSNK2A1 159/4885GSK3B 263/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.